Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W0NU
|
||||
| Former ID |
DNCL001978
|
||||
| Drug Name |
NIC5-15
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 2 | [1] | ||
| Company |
Humanetics Minneapolis, MN
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C7H14O6
|
||||
| Canonical SMILES |
COC1C(C(C(C(C1O)O)O)O)O
|
||||
| InChI |
1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3/t2?,3-,4-,5-,6+,7?/m0/s1
|
||||
| InChIKey |
DSCFFEYYQKSRSV-FEPQRWDDSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
6581, 8588, 3155012, 3722559, 8144322, 11533103, 12015429, 15171584, 15195390, 16143257, 24867648, 32964008, 34883167, 42613911, 46238788, 48394212, 57350488, 57390994, 57392457, 74348299, 77606223, 91695992, 92297531, 93620589, 103069827, 103078090, 103612712, 104118995, 113454442, 117557283, 118046756, 119525293, 124365766, 127778904, 132570187, 135120758, 135653842, 136991802, 137147437, 139694673, 139694700, 143492567, 144106862, 144115877, 144233669, 152057788, 152164787, 152238566, 162224562, 162859147
|
||||
| Target and Pathway | |||||
| Target(s) | Amyloid beta A4 protein | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Notch signaling pathway | ||||
| Alzheimer's disease | |||||
| Reactome | Nuclear signaling by ERBB4 | ||||
| Degradation of the extracellular matrix | |||||
| Regulated proteolysis of p75NTR | |||||
| NRIF signals cell death from the nucleus | |||||
| Activated NOTCH1 Transmits Signal to the Nucleus | |||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
| EPH-ephrin mediated repulsion of cells | |||||
| WikiPathways | Notch Signaling Pathway | ||||
| Signaling by ERBB4 | |||||
| Signaling by NOTCH3 | |||||
| Signaling by NOTCH4 | |||||
| Signaling by NOTCH1 | |||||
| Signaling by NOTCH2 | |||||
| Notch Signaling Pathway | |||||
| Alzheimers Disease | |||||
| Signalling by NGF | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01928420) A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health. | ||||
| REF 2 | Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014 Nov;10(11):911-20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.